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Nine patients with chronic severe low output heart failure (radionuclide 
left ventricular ejection fraction 17 f 5 percent [mean f standard de- 
viation], left ventricular filling pressure 26 f 6 mm Hg, cardiac index 1.9 
f 0.4 litersimin per m2, left ventricular stroke work index 18 f 6 g-m/m2) 
from various causes were treated with intravenous prenalterol (a new 
catecholamine-like inotropic agent) in doses of 1, 4 and 6 mg. Significant 
hemodynamic improvement occurred as measured by increased left 
ventricular ejection fraction (to 26 f 4 percent), decreased lefl ventricular 
filling pressure (to 21 f 8 mm Hg) and increased cardiac index (to 2.4 
f 0.6 liters/min per m2) and left ventricular stroke work index (to 25 f 
8 g-m/m2). Significant increases in heart rate (from 87 f 18 to 91 f 18 
beats/min) and mean systemic arterial pressure (from 87 f 8 to 92 f 7 
mm Hg) also occurred. Peak hemodynamic response occurred at various 
doses. Significant adverse effects associated with prenalterol consisted 
of increased ventricular ectopic beats in two patients and asymptomatic 
ventricular tachycardia in two patients. Thus, intravenous prenalterol 
produces hemodynamic improvement in patients with a chronic severe 
low output state but may be associated with increased ventricular ectopic 
activity. 
Prenalterol (levorotatory form of 1-isopropylamino-3-[p-hydroxy- 
phenoxyl-Z-propanol hydrochloride) is a new catecholamine-like cardiac 
inotropic agent which has been shown in anima11T2 and human3-9 studies 
to possess relatively selective beta1 adrenergic stimulating properties, 
resulting in a positive inotropic response with acceptable chronotropic 
and vasoactive properties. Because it is effective both orally and par- 
enterally, it has been proposed for use in the therapy of both acute and 
chronic heart failure, including potential use as an adjunct or substitute 
for cardiac glycoside therapy in selected patients. The current study was 
undertaken to provide an evaluation of the hemodynamic effects of in- 
travenously administered prenalterol in patients with severe low output 
heart failure. 
Methods 
Study patients: Nine patients (mean age 59 f 7 years) with chronic severe 
symptomatic heart failure (New York Heart Associationlo functional class II 
to IV; left ventricular filling pressure, determined from mean pulmonary arterial 
wedge pressure, greater than or equal to 16 mm Hg; and left ventricular ejection 
fraction less than or equal t.o 30 percent) were included. Seven of the nine pa- 
tients were in the cardiac intensive care unit for management of heart failure 
at the time of investigation. Six patients had ischemic heart disease, two had 
idiopathic failure and one had alcoholic cardiomyopathy. The clinical diagnosis 
of severe left ventricular dysfunction was substantiated by cardiac catheter- 
ization with selective coronary angiography in seven patients, and in the re- 
maining two patients it was supported by M mode echocardiography. 
Before study, a complete history was obtained and physical examination was 
performed with emphasis placed on New York Heart Association functional class 
and signs of heart failure. Five patients were chronically digitalized with oral 
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digoxin at the time of investigation in doses ranging from 0.125 
to 0.25 mg daily. Serum digoxin levels in digitalized patients 
obtained within 1 to 6 days of prenalterol administration 
ranged from 0.26 to 1.05 mg/ml (tiean 0.74). No patient had 
clinical evidence of digitalis toxicity. All patients required 
chronic diuretic therapy. Prior antiarrhythmic therapy in two 
patients (disopyramide, 100 mg orally four times daily, in 
Patient 8 and quinidine sulfate, 200 mg orally four times daily, 
in Patient 9), was continued throughout the study. Vasodi- 
lators were withheld for 24 hours. Digitalis and diuretic agents 
were administ.ered at least 6 hours before and antiarrhythmic 
medications were withheld during administration of the in- 
vestigational agent. Patients with unstable angina, acute 
myocardial infarction within 3 months or hvpertrophic car- 
diomyopathy were excluded. The investigative protocol was 
approved by the Human Use Committee of the University of 
Michigan Medical Center, and written informed consent was 
obtained from each patient before study. 
Hemodynamic measurements: All patients were studied 
in the postabsorptive state after placement of a flow-directed 
pulmonary arterial thermodilut.ion catheter. Systemic arterial 
pressure was monitored by radial or brachial arterial catheter 
(seven patients) or sphygmomanometer (two patients). Heart 
rate was determined from the electrocardiogram. Other he- 
modynamic variables were determined as follows: Cardiac 
output was determined in eight patients by thermodilution 
technique (10 cc of iced 5 percent dextrose m water injected 
by pneumatic pump) and in one patient by indocyanine green 
using a Lexington cardiac output computer. The mean of 
triplicate thermodilution or duplicate green dye values was 
determined at each interval. Pulmonary arterial systolic and 
diastolic pressures and mean pulmonary arterial, mean pul- 
monary arterial wedge and mean right atria1 pressures were 
obtained directly from the flotation catheter connected to 
Statham P23DB pressure transducers recorded on an Elec- 
tronics for Medicine VR12 recorder. Derived hemodynamic 
variables were obtained from standard formulas. Left ven- 
tricular filling pressure was determined from mean pulmonary 
arterial wedge pressure. 
Radionuclide studies: Left ventricular ejection fraction 
was determined by equilibrium radionuclide gated cardiac 
blood pool imaging using 10 to 20 mCi of technetium-99m for 
in vivo labeling of circulating red blood cells. A gamma camera 
oriented in the modified left anterior oblique position was 
used for cardiac blood pool imaging. Technically satisfactory 
radionuclide studies were obtained in eight of the nine pa- 
tients. 
Other laboratory studies: Continuous 24 hour electro- 
cardiographic (Halter) monitoring was obtained on the day 
of the study for arrhythmia analysis. A minimum of 8 hours 
of electrocardiographic monitoring was recorded before ad- 
ministration of the investigational drug. Chest roentgenog- 
raphy, 12 lead electrocardiography, complete blood count, 
platelet count, reticulocyte count, prothrombin time, partial 
thromboplastin time, urine analysis and determination of 
SMA 12 blood chemistry values, electrolytes and cardiac en- 
zymes (creatine kinase with isoenzyme pattern, lactic dehy- 
drogenase with isoenzyme pattern and serum glutamic ox- 
aloacetic transaminase analysis) were performed before ad- 
ministration of prenalterol. Analysis of all laboratory data 
except the chest roentgenogram was repeated after drug ad- 
ministration and compared with pretreatment values. 
Prenalterol administration: After two cont,rol measure- 
ments in the resting &ate, intravenous prenalterol was ad- 
ministered through a peripheral intravenous line in doses of 
I,4 and 8 mg at 30 minute intervals. Each dose was given over 
5 minutes by infusion pump, and hemodynamic measure- 
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ments were performed over 5 minutes beginning 10 and 25 
minutes after 1 and 4 mg doses and 10, L’5 and 55 minutes after 
8 mg doses. The mean of two baseline control values was used 
for comparison with values after drug administration. 
Statistical analysis: All values were expressed as mean f 
standard deviation. Statistical analysis was performed using 
t.he paired t test. A probability (p) value of less than or equal 
to 0.05 was considered statistically significant. 
Results 
Severe chronic impairment. of left ventricular func- 
tion was present in all patients. Eight of the nine pa- 
tients had had symptoms of heart failure for at least 1 
year and one patient had had such symptoms for 4 
months. Six patients were in New York Heart Associ- 
ation functional class IV, two were in class III and one 
patient was in class II. Eight of the nine patients had a 
left ventricular third heart sound (Ss) at the t.ime of 
study, and seven had received venous or arterial vaso- 
dilator therapy for refractory heart failure. 
Hemodynamic effects of prenalterol: Hemody- 
namic data revealed significant improvement, in cardiac 
index and left ventricular stroke work index and ejec- 
tion fraction associated with a decrease in left ventric- 
ular filling pressure (Table I, Fig. I). Statistically sig- 
nificant increases in systemic and mean arterial pres- 
sures and heart rate occurred as well. Diastolic arterial 
pressure and syst,emic arteriolar resistance did not 
change significantly. Pulmonary vascular resistance and 
mean right atria1 pressure decreased significantly. In- 
creases in right ventricular stroke work index were 
nearly statistically significant (p CO.06). No significant 
differences were noted among the three doses, and the 
peak hemodynamic effect occurred variably after the 
I,4 or 8 mg doses. 
Effect on ventricular arrhythmia: No adverse 
hemodynamic effects were noted except for a transient 
asympt.omatic decrease in ejection fraction, cardiac 
index and stroke work index in Patient 4. Electrocar- 
diographic monitoring revealed ectopic ventricular 
complexes during the control period in all patients. 
During subsequent drug administration, two patients 
had an increased number of ventricular ectopic com- 
plexes, and transient unsustained asymptomatic ven- 
tricular tachycardia developed in two patients. Patient 
5 had had frequent three beat ventricular tachycardia 
before drug administration and a prolonged (172 beat) 
run of ventricular tachycardia after drug administra- 
tion. Prenalterol administration was discontinued in 
this patient and no further ventricular tachycardia was 
noted on subsequent 24 hour monitoring. Patient 7 
manifested a nine beat ventricular tachycardia after 
drug administration without previous or subsequent 
ventricular tachycardia. Both Patients 5 and 7 received 
concomitant digoxin therapy at the time of study. 
Prenalterol therapy was discontinued in Patient 6 after 
administration of 4 mg because the number of ventric- 
ular ectopic complexes increased. 
Adverse effects: All patients tolerated prenalterol 
administration without subjective complaints of angina 
pectoris, palpitations, worsening shortness of breath or 
other symptoms. No electrocardiographic signs of in- 
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creased ischemia were noted during drug administra- 
t.ion. Evaluation of laboratory values after drug ad- 
ministration revealed no adverse effeck on hematologic, 
hepatic or cardiac variables, including cardiac enzyme 
analysis. 
Discussion 
Recent advances in the medical management of low 
output heart. failure include the introduction of vaso- 
dilator therapy for ventricular preload and afterload 
reduction as well as the introduction of the potent new 
parenteral inotropic agents dopamine and dobutamine. 
However, the only oral inotropic agents currently 
TABLE I 
Characteristics of Patients and Response to Prenalterol 
Patients 
available for clinical use are the cardiac glycosides, 
which are associated with a significant incidence of 
toxicity, including life-threatening cardiac arrhyth- 
mias.11 Digitalis cardiac toxicity may be enhanced by 
the frequent concurrent administration of potassium- 
depleting diuretic drugs and quinidine, which signifi- 
cantly increases serum digoxin levels and thereby may 
increase myocardial glycoside concentration to toxic 
levels.” In addition, several investigators have sug- 
gested that chronic cardiac glycoside therapy may be 
ineffective in some patients with heart failure, as evi- 
denced by a return to pretreatment hemodynamic sta- 
tus upon withdrawal of chronic digitalis therapy.13-l6 
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* Patient 5 had ventricular tachycardia after a 1 mg infusion and was excluded from further analysis. t Technically unsatisfactory radionuclide 
cardiac blood pool scan. 
_fJEF = left ventricular ejection fraction; LVFP = left ventricular filling pressure; LVBI = left ventricular stroke work index; NA = not available; 
PAP = mean pulmonary arterial pressure: PAR = pulmonary arteriolar resistance; RAP = mean right atrial pressure; RVSWI = right ventricular 
stroke work index: SAR = systemic arteriolar resistance. 
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Because cardiac glycosides remain less than ideal agents 
for chronic inotropic therapy of heart failure despite 2 
centuries of use, other orally effective inotropic agents 
are being actively investigated. 
Pharmacologic features of prenalterol: The new 
inotropic agent prenalterol is a derivative of phenol with 
a chemical structure resembling the catecholamine 
isoproterenol. The presumed mechanism of action is 
stimulation of cardiac beta1 adrenergic receptors, which 
appears to be mediated directly since reserpine-treated 
animals maintain an inotropic response after adminis- 
tration of prenalterol.’ It is effective both parenterally 
and orally and has relatively selective inotropic effects 
with a smaller effect on heart rate and systemic arterial 
pressure. 
Animal studies by Carlsson et al.’ demonstrated 
dose-dependent increases in the rate of rise of left 
ventricular pressure (dP/dt) after intravenous prenal- 
terol with fewer chronotropic and arterial vasodilating 
properties than isoproterenol or terbutaline. Oral ad- 
ministration of 5 to 20 mg of prenalterol by Knaus et al.” 
to normal volunteers resulted in shortened systolic time 
intervals with significant increases in heart rate and 
systolic arterial pressure and a transient decrease in 
diastolic arterial pressure. Sinus arrhythmias increased 
significantly with no increase in ventricular or supra- 
ventricular extrasystoles. The inotropic effects of pre- 
nalterol in normal volunteers are blocked by the selec- 
tive beta1 adrenergic blocking agent metoprolol.” 
Pharmacokinetic data in normal volunteers demon- 
strated a mean plasma half-life of 2 hours aft.er intra- 
venous administration of prenalt,erol,” compared with 
a plasma half-life of 2 minutes for dobutamine.” Pre- 
nalterol’s electrophysiologic properties include short- 
ened atrioventricular nodal conduction time and atria1 
refractory period.18 
Clinical hemodynamic effects of prenalterol: 
Previous clinical investigations in patients with cardiac 
disease have also demonstrated beneficial hemody- 
namic effects. Hutton et a1.s demonstrated increased 
left ventricular dP/dt after intravenous administration 
of prenalterol in patients with ischemic heart disease 
without changes in heart rate or end-diastolic volume. 
Prenalterol reversed the decreased heart rate, blood 
pressure and cardiac output and the increased pre- 
ejection period after adrenergic blockade with me- 
toprolol following acute myocardial infarction.” A pre- 
liminary study of oral prenalterol in patients with severe 
heart failure (functional classes III and IV) showed 
beneficial effects on left ventricular filling pressure, 
cardiac index, ejection fraction and exercise tolerance.’ 
Hypotension induced by spinal anesthesia has been 
reversed by prenalterol. lg No significant adverse effects 
have previously been reported after administration of 
prenalterol. 
The possibility that prolonged administration of 
prenalterol may be associated with a diminished re- 
sponse, a phenomenon noted with other adrenergic 
stimulantGo including dobutamine,21 has not been in- 




FIGURE 1. Effects of prenalterol on selected hemodynamic variables. 
Values are expressed as mean f standard deviation for control state 
before drug administration and at peak effect. HR. = heart rate; LVEF 
= left ventricular ejection fraction; LVFP = left ventricular filling 
pressure; LVSWI = left ventricular stroke work index: MAP = mean 
arterial pressure. 
compared with other inotropic agents such as dobuta- 
mine and dopamine have not been reported. 
The present study demonstrates significant im- 
provement in hemodynamic status after intravenous 
administration of prenalterol. However, our investiga- 
tion differs from most previous studies in that only 
patients with severe low output failure are included. In 
our study, improved left ventricular performance is 
demonstrated by statistically significant increases in 
left ventricular ejection fraction, left ventricular stroke 
work index and cardiac index. Diminished left ven- 
tricular filling pressure may be due to a direct posibive 
inotropic effect resulting in decreased left ventricular 
end-diastolic volume or due to left ventricular preload 
reduction from systemic venodilation, or both. The 
significant reduction in right atria1 pressure in our study 
suggests a systemic venodilating effect. The net hemo- 
dynamic effect is a shift in the ventricular function 
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curve upward and to the left, as found with other ino- 
tropic agents. A statistically significant increase in heart 
rate after prenalterol indicates a residual chronotropic 
effect, which may be mediated by stimulation of cardiac 
beta1 adrenergic receptors affecting heart rat.e. The 
increase in systolic and mean arterial pressures achieved 
statistical significance; however, diastolic arterial 
pressure did not change significantly. These findings 
are in agreement with those of previous studies.4T5 A 
decrease in systemic vascular resistance after admin- 
istration of prenalterol suggests that the increased 
systolic and mean arterial pressures are related to in- 
creased cardiac contractile force rather than arterial 
vasoconstriction. Significant left ventricular afterload 
reduction, either by direct beta adrenergic arterial 
vasodilation or by reflex withdrawal of heightened 
sympathetic vasoconstrictor tone, is a mechanism by 
which beta adrenergic stimulants can improve left 
ventricular performance.** 
Inotropic effect in the presence of myocardial 
ischemia: The decrease in abnormally elevated pul- 
monary vascular resistance after administration of 
prenalterol in this study is comparable with similar 
changes noted with dobutamine.22 There was consid- 
erable variation in the patients’ response to prenalterol 
(Table I). Although increases in heart rate and systemic 
systolic and mean arterial pressure achieved statistical 
significance, it is unlikely that the modest nature of 
these changes would be harmful in most patients. In 
individual patients, increased ischemia could result 
from increases in myocardial oxygen consumption (re- 
flected by an increased pressure-rate product) greater 
than the increase in blood flow to ischemic tissue caused 
by beta1 adrenergic stimulation.23 However, no sub- 
jective or objective evidence of aggravated ischemia was 
present in this study or that of Ariniego et a1.,5 who 
evaluated prenalterol therapy after recent myocardial 
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dobutamine, was not shown to exert an adverse effect 
on the size of myocardial infarction in experimental 
animals2” and in patients.“5 
Prenalterol and ventricular arrhythmia: The only 
adverse effects found in this study were cardiac ar- 
rhythmias. Although catheter-induced arrhythmias or 
,arrhythmias related to the underlying disease cannot 
be excluded, the temporal association of the arrhyth- 
mias with drug administration suggests a causal rela- 
tion. Ventricular ectopic activity has been observed with 
other inotropic agents including the catecholamine 
dobutamine26 and dopamine,27 and these agents may 
have been equally arrhythmogenic in the patients in- 
cluded in this study. Both patients with ventricular 
tachycardia after administration of prenalterol in this 
investigation received chronic oral digoxin therapy 
(with serum levels in the therapeutic range) for ischemic 
congestive cardiomyopathy after myocardial infarction, 
raising the possibility that the combination of prenal- 
terol or other adrenergic inotropic agents and digoxin 
may induce serious ventricular arrhythmias. Increased 
sympathetic activity has been associated with digitalis 
toxicity28 and, conversely, beta adrenergic blockade has 
been found to be of value in the therapy of digitalis- 
induced cardiac arrhythmias.2g Two of our five patients 
receiving long term oral digoxin therapy did not leave 
an increase in ventricular ectopic activity. However, the 
combination of severe ischemic heart failure and pre- 
vious digoxin therapy appears to warrant particular 
caution in the administration of prenalterol. 
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